The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Q-TWiST analysis from the QUANTUM-First trial: evaluating quality-adjusted survival in AML
Esther Oliva, MD, London North West University Healthcare NHS Trust, London, UK, shares insights into the Q-TWiST (Quality-adjusted Time Without Symptoms or Toxicity) analysis from the QUANTUM-First (NCT02668653) trial, evaluating quality-adjusted survival in patients with acute myeloid leukemia (AML). She highlights that Q-TWiST provides a more patient-centered understanding of treatment benefits and suggests that it should complement traditional endpoints. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
